AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Phase 4
Recruiting
- Conditions
- Mild Asthma
- Interventions
- Combination Product: Albuterol/BudesonideCombination Product: Albuterol
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06563102
- Locations
- 🇺🇸
Research Site, Waco, Texas, United States
A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT06555822
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06554821
- Locations
- 🇩🇪
Research Site, Berlin, Germany
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06548152
A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Phase 3
Recruiting
- Conditions
- Untreated Follicular Lymphoma
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1015
- Registration Number
- NCT06549595
- Locations
- 🇬🇧
Research Site, Norwich, United Kingdom
Imjudo & Imfinzi PMS
Recruiting
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 246
- Registration Number
- NCT06544629
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06547164
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 174
- Registration Number
- NCT06542250
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Phase 2
Recruiting
- Conditions
- Cervical CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06535607
- Locations
- 🇨🇳
Research Site, Wuhan, China
© Copyright 2025. All Rights Reserved by MedPath